Ph3 MK2870 with or without pembro in HR+ HER2 metastatic breast cancer
Phase III Clinical Trial
An Open-label Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)